Evidence map›Paper›PMID 36397137›Full record

ArticleInfectious agents and cancer2022

EBV persistence in gastric cancer cases conventionally classified as EBER-ISH negative.

M C Siciliano, S Tornambè, G Cevenini, E Sorrentino, M Granai, G Giovannoni, D Marrelli, I Biviano, F Roviello, H Yoshiyama and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious agents and cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Cancers · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

M C Siciliano *Section of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
S Tornambè *Section of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
G CeveniniDepartment of Medical Biotechnology, University of Siena, Siena, Italy.
E SorrentinoSection of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
M GranaiInstitut Für Pathologie und Neuropathologie Abt. Allgemeine und Molekulare Pathologie und Pathologische Anatomie University of Tubingen, Tübingen, Germany.
G GiovannoniSection of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
D MarrelliDepartment of Human Pathology and Oncology, Surgical Oncology, Siena University, Siena, Italy.
I BivianoGastroenterology Unit, A.O.U.S. Policlinico S. Maria alle Scotte, Siena, Italy.
F RovielloDepartment of Human Pathology and Oncology, Surgical Oncology, Siena University, Siena, Italy.
H YoshiyamaDepartment of Microbiology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.
L LeonciniSection of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy. lorenzo.leoncini@dbm.unisi.it.
S LazziSection of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
L MundoSection of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
University of Siena · ITOspedale Santa Maria alle Scotte · ITShimane University · JPUniversity of Limerick · IEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Epstein-Barr virus (EBV) causes various B-cell lymphomas and epithelial malignancies, including gastric cancer (GC) at frequencies ranging from 5 to 10% in adenocarcinomas (ADK) to 80% in GC with lymphoid stroma (GCLS). Using high-sensitivity methods, we recently detected EBV traces in a large cohort of EBV-negative B-cell lymphomas, suggesting a hit-and-run mechanism.

methodsHere, we used routine and higher-sensitivity methods [droplet digital PCR (ddPCR) for EBV segments on microdissected tumour cells and RNAscope for EBNA1 mRNA] to assess EBV infection in a cohort of 40 GCs (28 ADK and 12 GCLS).

resultsddPCR documented the presence of EBV nucleic acids in rare tumour cells of several cases conventionally classified as EBV-negative (ADK, 8/26; GCLS, 6/7). Similarly, RNAscope confirmed EBNA1 expression in rare tumour cells (ADK, 4/26; GCLS, 3/7). Finally, since EBV induces epigenetic changes that are heritable and retained after complete loss of the virus from the host cell, we studied the methylation pattern of EBV-specifically methylated genes (Timp2, Eya1) as a mark of previous EBV infection. Cases with EBV traces showed a considerable level of methylation in Timp2 and Eya1 genes that was similar to that observed in EBER-ISH positive cases and greater than cases not featuring any EBV traces.

conclusionsThese findings suggest that: (a) EBV may contribute to gastric pathogenesis more widely than currently acknowledged and (b) indicate the methylation changes as a mechanistic framework for how EBV can act in a hit-and-run manner. Finally, we found that the viral state was of prognostic significance in univariate and multivariate analyses.

Indexed as

Epstein Barr VirusGastric adenocarcinomaGastric cancer with lymphoid stromaHit and run mechanism

Identifiers

PMID36397137
PMCPMC9673334
OpenAlexW4309467654

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.